IDH2 and neoplasm: SIRT3 deacetylates IDH2 at K413, which activates its enzymatic activity by promoting IDH2 dimer formation, subsequently reducing intracellular ROS and glycolysis, and inhibiting the tumour‐prone phenotype.260, 261, 262